A detailed history of Group One Trading, L.P. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 98,945 shares of RLMD stock, worth $277,046. This represents 0.01% of its overall portfolio holdings.

Number of Shares
98,945
Previous 148,927 33.56%
Holding current value
$277,046
Previous $446,000 28.25%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.3 - $4.36 $114,958 - $217,921
-49,982 Reduced 33.56%
98,945 $320,000
Q2 2024

Aug 14, 2024

SELL
$2.93 - $4.94 $103,754 - $174,930
-35,411 Reduced 19.21%
148,927 $446,000
Q1 2024

May 10, 2024

BUY
$3.1 - $6.8 $80,324 - $176,194
25,911 Added 16.36%
184,338 $857,000
Q4 2023

Feb 14, 2024

SELL
$2.45 - $4.22 $5,086 - $8,760
-2,076 Reduced 1.29%
158,427 $655,000
Q3 2023

Nov 09, 2023

BUY
$2.48 - $3.79 $59,391 - $90,762
23,948 Added 17.54%
160,503 $481,000
Q2 2023

Aug 09, 2023

BUY
$2.22 - $3.54 $206,151 - $328,727
92,861 Added 212.53%
136,555 $335,000
Q1 2023

May 12, 2023

SELL
$2.24 - $4.76 $223,643 - $475,243
-99,841 Reduced 69.56%
43,694 $98,000
Q4 2022

Feb 09, 2023

BUY
$2.17 - $35.84 $311,470 - $5.14 Million
143,535 New
143,535 $500,000
Q2 2022

Aug 11, 2022

BUY
$16.5 - $30.34 $55,341 - $101,760
3,354 New
3,354 $64,000
Q4 2021

Feb 11, 2022

SELL
$16.93 - $26.82 $34,452 - $54,578
-2,035 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$21.86 - $34.77 $113,344 - $180,282
-5,185 Reduced 71.81%
2,035 $53,000
Q2 2021

Aug 10, 2021

BUY
$29.55 - $39.15 $29,550 - $39,150
1,000 Added 16.08%
7,220 $231,000
Q1 2021

May 12, 2021

BUY
$31.52 - $39.28 $196,054 - $244,321
6,220 New
6,220 $219,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $80.1M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.